Jpmorgan Chase & Company Has Lifted Cabot (CBT) Position, Pacira Pharmaceuticals (PCRX) SI Decreased By 4.53%

July 17, 2017 - By Richard Conner

Pacira Pharmaceuticals Incorporated (NASDAQ:PCRX) had a decrease of 4.53% in short interest. PCRX’s SI was 3.10M shares in July as released by FINRA. Its down 4.53% from 3.25M shares previously. With 543,000 avg volume, 6 days are for Pacira Pharmaceuticals Incorporated (NASDAQ:PCRX)’s short sellers to cover PCRX’s short positions. The SI to Pacira Pharmaceuticals Incorporated’s float is 8.8%. About 16,521 shares traded. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has risen 12.40% since July 17, 2016 and is uptrending. It has underperformed by 4.30% the S&P500.

Jpmorgan Chase & Company increased Cabot Corp (CBT) stake by 10.19% reported in 2016Q4 SEC filing. Jpmorgan Chase & Company acquired 105,785 shares as Cabot Corp (CBT)’s stock declined 11.34%. The Jpmorgan Chase & Company holds 1.14 million shares with $57.83M value, up from 1.04M last quarter. Cabot Corp now has $3.39B valuation. The stock rose 0.33% or $0.18 reaching $53.99 per share. About 17,338 shares traded. Cabot Corp (NYSE:CBT) has risen 15.44% since July 17, 2016 and is uptrending. It has underperformed by 1.26% the S&P500.

Jpmorgan Chase & Company decreased Williams Partners LP New (ACMP) stake by 205,830 shares to 4.04M valued at $153.54M in 2016Q4. It also reduced Discovery Communicatns New (NASDAQ:DISCK) stake by 97,544 shares and now owns 228,659 shares. Vonage Hldgs Corp (NYSE:VG) was reduced too.

Among 6 analysts covering Cabot (NYSE:CBT), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Cabot had 11 analyst reports since August 13, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, June 8 by Jefferies. The firm has “Neutral” rating given on Monday, March 14 by JP Morgan. Deutsche Bank maintained Cabot Corp (NYSE:CBT) on Wednesday, November 11 with “Buy” rating. The firm has “Buy” rating by BB&T Capital given on Thursday, December 10. The stock has “Buy” rating by Jefferies on Thursday, July 13. The stock has “Sector Weight” rating by KeyBanc Capital Markets on Monday, April 11. Deutsche Bank maintained Cabot Corp (NYSE:CBT) rating on Thursday, August 13. Deutsche Bank has “Hold” rating and $37.0 target. Deutsche Bank maintained the stock with “Hold” rating in Friday, August 12 report. The company was upgraded on Tuesday, September 1 by Zacks. The stock of Cabot Corp (NYSE:CBT) earned “Neutral” rating by SunTrust on Tuesday, August 2.

Since January 24, 2017, it had 0 insider buys, and 12 sales for $25.49 million activity. BERUBE BRIAN A sold $2.26M worth of Cabot Corp (NYSE:CBT) on Monday, February 6. 15,909 shares were sold by von Gottberg Friedrich, worth $913,495 on Monday, February 6. Shares for $3.59 million were sold by Prevost Patrick M.. Another trade for 7,000 shares valued at $404,530 was made by Cross Nicholas S. on Monday, February 6. 2,500 Cabot Corp (NYSE:CBT) shares with value of $137,375 were sold by Kelly James Patrick. 37,695 shares were sold by CORDEIRO EDUARDO E, worth $2.17 million. Kalkstein Hobart sold $437,938 worth of stock.

Investors sentiment increased to 0.97 in 2016 Q4. Its up 0.03, from 0.94 in 2016Q3. It increased, as 27 investors sold CBT shares while 96 reduced holdings. 37 funds opened positions while 82 raised stakes. 52.20 million shares or 1.06% less from 52.76 million shares in 2016Q3 were reported. Ajo Limited Partnership reported 313,953 shares or 0.07% of all its holdings. Vanguard Group Inc reported 5.40 million shares. Aureus Asset Mngmt Limited Liability Company holds 131,824 shares. Teachers Retirement Sys Of The State Of Kentucky invested in 12,000 shares. Opus Gp Ltd Co holds 5,104 shares. 33,603 were accumulated by State Of Wisconsin Board. Oregon Public Employees Retirement Fund holds 0.02% of its portfolio in Cabot Corp (NYSE:CBT) for 21,560 shares. Gemmer Asset Mngmt Llc holds 0% in Cabot Corp (NYSE:CBT) or 172 shares. United Kingdom-based Cantab Cap Limited Liability Partnership has invested 0% in Cabot Corp (NYSE:CBT). Cornerstone Management Liability Com reported 157,606 shares stake. Lsv Asset Mgmt reported 3.16 million shares or 0.29% of all its holdings. Invesco Limited invested 0.01% in Cabot Corp (NYSE:CBT). Patten Patten Inc Tn stated it has 21,918 shares. Breton Hill Cap Ltd holds 20,812 shares. Rhumbline Advisers has invested 0.02% of its portfolio in Cabot Corp (NYSE:CBT).

Pacira Pharmaceuticals, Inc. is a holding company. The company has market cap of $1.96 billion. The Firm is a pharmaceutical firm focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. It currently has negative earnings. The Company’s lead product candidate is EXPAREL , which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia.

Investors sentiment increased to 1.18 in 2016 Q4. Its up 0.08, from 1.1 in 2016Q3. It improved, as 21 investors sold Pacira Pharmaceuticals Inc shares while 53 reduced holdings. 34 funds opened positions while 53 raised stakes. 38.95 million shares or 1.71% more from 38.30 million shares in 2016Q3 were reported. Kanaly Tru holds 0% or 65 shares. Nationwide Fund Advisors holds 0% in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) or 22,708 shares. Northwestern Mutual Wealth Mgmt invested in 0% or 10 shares. Gilder Gagnon Howe And Communication Ltd Liability Corp stated it has 1.23 million shares. Highland Capital Mngmt Ltd Partnership has 70,679 shares. Partner Management L P holds 26,690 shares. 447,857 were accumulated by Elk Creek Prtn Limited Liability Company. Citadel Advsrs Ltd invested 0% in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Alyeska Inv Group Ltd Partnership reported 543,110 shares stake. Creative Planning accumulated 1,600 shares. Wellington Management Group Incorporated Llp invested in 0% or 25,691 shares. Dekabank Deutsche Girozentrale accumulated 20,015 shares. Synovus Financial Corp has 65 shares for 0% of their portfolio. Guggenheim Llc holds 0.01% or 68,588 shares in its portfolio. Oak Ridge Limited Liability owns 0.56% invested in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) for 534,924 shares.

Among 16 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 10 have Buy rating, 1 Sell and 5 Hold. Therefore 63% are positive. Pacira Pharmaceuticals had 34 analyst reports since July 28, 2015 according to SRatingsIntel. Canaccord Genuity initiated the stock with “Buy” rating in Wednesday, February 22 report. The stock has “Buy” rating by Mizuho on Thursday, November 3. Brean Capital downgraded the shares of PCRX in report on Friday, July 1 to “Hold” rating. On Wednesday, May 24 the stock rating was maintained by Wedbush with “Buy”. Wedbush maintained the stock with “Outperform” rating in Thursday, August 20 report. The rating was maintained by Wedbush with “Buy” on Wednesday, June 21. The company was maintained on Tuesday, May 3 by Mizuho. Bank of America upgraded the stock to “Buy” rating in Friday, January 29 report. On Wednesday, October 19 the stock rating was maintained by Wedbush with “Outperform”. The firm has “Outperform” rating by Wedbush given on Wednesday, March 22.

Since May 15, 2017, it had 0 insider purchases, and 9 sales for $2.59 million activity. 601 shares were sold by Riker Lauren Bullaro, worth $26,036 on Monday, June 5. $186,757 worth of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) was sold by STACK DAVID M. Scibetta James S sold 20,000 shares worth $1.02M. Jones James B also sold $33,227 worth of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) on Monday, June 5. On Monday, June 5 Braunstein Scott sold $33,271 worth of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) or 768 shares. $81,314 worth of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) was sold by Williams Kristen Marie on Monday, June 5.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.